How Lumea Technology Delivers a 35% Reduction in Prostate Fragmentation

Abstract

This study evaluates the impact of a specialized pre-analytical stabilization workflow on the physical integrity of prostate needle core biopsies. Traditional handling methods often result in specimen fragmentation and tortuosity, leading to significant diagnostic and operational inefficiencies. Using a comparative analysis of 2,812 specimens, we demonstrate that the Lumea BxBoard® and BxChip® system reduces tissue breakage by 35% (p<0.001) and maintains superior linear orientation. These findings suggest that stabilizing tissue at the point of collection mitigates pre-analytical artifacts, optimizes downstream histopathological processing, and provides a standardized substrate for digital pathology and Artificial Intelligence (AI) integration.

Introduction

In the histopathology workflow, the pre-analytical phase (the period from tissue extraction to completion of fixation) is responsible for up to 92.9% of all laboratory non-conformities.¹ For prostate core biopsies, the primary indicators of specimen quality are fragmentation and tortuosity (curling). Fragmentation increases the risk of “floaters” and complicates cancer quantification, while tortuosity leads to inconsistent surface area (due to linear variability) during microtomy. This study quantifies how a fixed-lane stabilization system (BxBoard and BxChip) improves these metrics compared to traditional “loose core” immersion.

Materials and Methods

A single-site comparative study was conducted evaluating a total of 2,812 prostate biopsy cores.

Specimen Groups

• Control Group (n=1,627): Specimens were collected via traditional core needle biopsy and placed into formalin bottles for transport, followed by unconstrained placement in standard cassettes.
• Experimental Group (n=1,185): Specimens were collected and immediately placed into the dedicated lanes of the Lumea BxBoard. Upon arrival at the laboratory, these specimens were transitioned into the BxChip, a tissue-mimetic matrix, for standardized processing.

Measurement Criteria

• Fragmentation Rate: Defined as the mean number of discrete tissue breakpoints per core identified during grossing and confirmed via digital slide review.
• Tortuosity Index: Calculated as the ratio of the curvilinear length of the tissue to the straight-line distance between the two most distant points of the core.
• Statistical Analysis: Fragmentation rates for the standard and Lumea workflows were compared using Poisson generalized estimating equations (GEE) with an exchangeable case-level correlation structure. Tortuosity was compared using Mann-Whitney U test.

Results

The implementation of the Lumea workflow resulted in a statistically significant improvement across all primary stability metrics (see Table 1). The mean fragmentation rate decreased from 2.0 breakpoints in the control group to 1.3 in the experimental group, representing a 35% reduction in breakage.

Table 1: Comparison of Specimen Stability Metrics: Traditional vs. Lumea

Metric	Traditional (n=1,627)	Lumea Workflow (n=1,185)	Impact
Fragmentation (Mean)	2.0 breakpoints	1.3 breakpoints	35% reduction*
Tortuosity (Median)	1.07 (IQR 1.04, 1.14)	1.02 (IQR 1.02, 1.03)	Significant straightening*

*Statistically significant (p<0.001).

Discussion

Mechanical Stabilization and Physics of Fixation

The reduction in fragmentation is attributed to the mechanical stabilization provided by the BxBoard’s lane-based architecture. Traditional immersion allows cores to move freely, subjecting them to fluid turbulence and mechanical friction. The BxBoard utilizes 0.35 mm narrow lanes that provide lateral support, neutralizing the kinetic energy that typically leads to mid-core fractures. Furthermore, the BxChip prevents the “coiling” effect that occurs when tissue proteins undergo cross-linking while in an unconstrained state.

Clinical and Economic Impact

Preserving core integrity has profound implications for diagnostic accuracy. Fragmentation forces pathologists to estimate cancer volume across multiple pieces, increasing variability in Gleason scoring. This is exacerbated by the “diagnostic paradox,” where aggressive high-grade tumors (which require the most precise grading) are found to be more prone to fragmentation than lower-grade specimens.² Operationally, this standardized orientation reduces manual “salvage” time, contributing to a reported 76% reduction in total laboratory processing time and an 83% reduction in embedding time.³

Expanded Discussion: Clinical and Contextual Implications

Clinical Utility: Diagnostic Precision and Integrity

In prostate pathology, the Gleason Score and the maximal cancer length (MCL) are the primary determinants of patient management. Traditional fragmented specimens force a “reconstructive” approach to grading, where the pathologist must aggregate measurements across multiple fragments, increasing the risk of over- or under-estimating tumor volume. By delivering more intact specimens, the Lumea workflow ensures linear continuity, allowing for a more accurate assessment of the tumor’s true extent.

Peer-Reviewed Support for Fragmentation and Morphometric Standardization

The findings of this study align with broader uropathological research identifying fragmentation as a significant driver of staging errors. Research indicates that traditional workflows suffer from an overall fragmentation rate of approximately 29.3%.⁴ This breakage is highly sensitive to modifiable procedural factors: submitting multiple cores per container triples the fragmentation rate from 14% to 41%.⁴ The BxBoard’s site-specific lanes directly counteract these variables by enforcing a one-core-per-lane standard. So, even when fragmentation does occur in the BxBoard and BxChip method, the fragments are kept together in order as a clearly identifiable “single core”.

Maintaining core length is a critical predictor of diagnostic yield. Cores returning a malignant diagnosis are consistently longer than benign ones (mean 12.3 mm vs 11.4 mm), with a length greater than 11.9 mm associated with a 2.57 times higher likelihood of detection.⁵,⁶ A median sample length of 12 mm is now considered the “ideal lower limit” for quality assurance.⁶ The integrity and length of the biopsy specimen significantly dictate the accuracy of risk stratification. Fragmentation or suboptimal sampling that results in cores shorter than the 11.4 mm threshold significantly compromises the ability to detect higher-grade patterns, leading to a higher rate of discordance.⁷

Mitigating Diagnostic Ambiguity: Curling and ASAP

Tissue curling and tortuosity introduce mechanical compression and tangential distortion that can result in ambiguous “atypical” diagnoses. Technical limitations and subsequent crush artifacts related to unconstrained coiling are known to lead to “Atypical Small Acinar Proliferation” (ASAP) reports.⁸ These ambiguous findings trigger stressful repeat biopsies in up to 5% of cases.⁸ By stabilizing tissue at the point of collection, the Lumea workflow provides better sample preparation, increasing the pathologist’s confidence and potentially reducing the incidence of ASAP.

Standardization in the Era of Precision Medicine and AI

The reduction in fragmentation is essential for advanced molecular profiling. Specimens collected using the BxBoard are 2.1 times less likely to be cancelled due to “Quantity Not Sufficient” (QNS) or RNA degradation (0.59% vs 1.27%).⁹ This preservation of genetic material ensures that patients can access critical genomic testing without requiring additional tissue sampling.

Finally, the 35% reduction in fragmentation provides an optimized input for digital pathology. Fragmentation introduces “edge effects” that can degrade the performance of AI algorithms. By ensuring straighter, intact cores, the Lumea system enhances pathologist-AI synergy, which has been shown to significantly increase grading agreement with expert standards compared to unassisted evaluation.¹⁰

Key Takeaways

• Fragmentation Mitigation: Mechanical stabilization at the point of collection reduces core breakage by 35% compared to traditional immersion.
• Modifiable Risk Control: Submitting multiple cores per container triples the rate of fragmentation (41% vs 14%). This risk is neutralized by the BxBoard’s site-specific lanes.⁴
• Gleason Grading Precision: Preserving linear integrity improves Gleason concordance with surgical pathology from 52.2% to 75.4%, significantly reducing the risk of undergrading aggressive disease.⁷
• Diagnostic Clarity: stabilization prevents the coiling and tangential distortion that contribute to equivocal ASAP diagnoses and unnecessary repeat biopsies.⁸
• Genomic Integrity: Preservation of tissue architecture reduces molecular test cancellations (QNS) by 2.1x, ensuring reliable access to precision diagnostics.⁹
• AI and Digital Readiness: Straighter, intact specimens optimize AI performance by reducing “edge effects” and artifacts, facilitating superior pathologist-AI synergy.¹⁰
• Operational Excellence: Standardized multiplexing reduces laboratory embedding time by 83% and total processing time by 76%.³

Conclusion

The Lumea BxBoard and BxChip system transforms tissue handling from a passive process into a controlled, protective framework. By significantly reducing fragmentation and tortuosity, the system establishes a new standard for pre-analytical core biopsy handling, maximizing both diagnostic quality and laboratory efficiency.

Ethical Declarations

Competing Interests: This study was conducted using proprietary technology developed by Lumea, Inc. Some authors may be employees of or hold equity in Lumea, Inc. The materials were provided by the manufacturer for the purposes of this study.

Data Availability: Data supporting these findings are available from the corresponding author upon reasonable request.

Clinical Note: ​​The proposed biopsy core length threshold of 11.4 mm is based on retrospective statistical analysis and should be interpreted as a quality benchmark rather than an absolute clinical mandate. Individual patient anatomy and surgeon judgment remain paramount.

 

References

1. Quality measures in pre-analytical phase of tissue processing: understanding its value in histopathology. J Cytol. 2016;33(1):7-11. doi:10.4103/0970-9371.175485
2. Fajardo DA, Miyamoto H, Miller JS, Netto GJ, Epstein JI. Fragmentation of prostatic needle biopsy cores containing adenocarcinoma: the role of specimen submission. Am J Surg Pathol. 2009;33(10):1472-1476. doi:10.1097/PAS.0b013e3181ad50e2
3. Murugan P, Shukla D, Morocho J, et al. Prostate biopsy processing: an innovative model for reducing cost, decreasing test time, and improving diagnostic material. Am J Clin Pathol. 2019;152(6):757-765. doi:10.1093/ajcp/aqz101
4. Shenoy K, Cote RJ, Kini G, Anthes-Bartlow M, Padmanabhan V. Is fragmentation of prostate core biopsies inevitable? A quality improvement initiative. Arch Pathol Lab Med. 2025;149(1):50-54. doi:10.5858/arpa.2023-0492-OA
5. Obek C, Dogan AS, Argun G, Kordan Y. Core length in prostate biopsy: size matters. J Urol. 2012;187(6):2051-2055. doi:10.1016/j.juro.2012.01.075
6. Fiset PO, Aprikian A, Brimo F. Length of prostate biopsy cores: does it impact cancer detection?. Can J Urol. 2013;20(4):6848-6853.
7. Guo CH, Geng YS, Zhu LY, Ding XF, Luan Y. The impact of biopsy core length on the discrepancy in Gleason scores between biopsy and radical prostatectomy specimen. BJUI Compass. 2025;6(3):e70009. Published 2025 Mar 4. doi:10.1002/bco2.70009
8. Iczkowski KA, MacLennan GT, Bostwick DG. Atypical small acinar proliferation suggestive of prostatic adenocarcinoma. Mod Pathol. 1998;11(3):224-230.
9. Diepeveen A. Reduce test cancellation 2.1x with the BxBoard® – a case study. Lumea Technology Insights. Published November 21, 2025. Accessed February 27, 2026. https://lumeadigital.com/white-paper-tissue-standardization/
10. Bulten W, Balkenhol M, Belinga JA, et al. Artificial intelligence assistance significantly improves Gleason grading of prostate biopsies by pathologists. Mod Pathol. 2021;34(3):660-671. doi:10.1038/s41379-020-0640-y